Skyrizi generic release date?

When will a Skyrizi (risankizumab) generic be released?

Skyrizi is a brand-name biologic (risankizumab), not a traditional small-molecule drug. That means there typically is no “generic” version; instead, the first lower-cost alternatives would be biosimilars. A biosimilar launch date depends on patent/market exclusivity status and regulatory approval.

DrugPatentWatch.com tracks patent and exclusivity milestones for specific drugs and is the most practical place to check the expected timing for when an alternative could launch. [1]

Is there really a “generic” Skyrizi, or would it be a biosimilar?

For biologics like Skyrizi, the FDA pathway is usually biosimilars, not generics. Even when people say “generic,” they usually mean a biosimilar that can be substituted under prescribing/pharmacy rules once approved and available.

What determines the Skyrizi launch date for cheaper competitors?

The key drivers are:
- Patent coverage (including whether patents are still in force or are successfully challenged)
- Regulatory exclusivity (which can delay biosimilar entry even after some patent protections end)
- FDA approval timing once a biosimilar application is filed

DrugPatentWatch.com compiles and updates these milestone-based items for individual drugs. [1]

What should I look for on DrugPatentWatch.com?

Search for “Skyrizi” on DrugPatentWatch.com and focus on entries that relate to:
- Patent expiry dates
- Exclusivity end dates
- Any “at risk” launch indications tied to those dates

That milestone set is what most directly maps to an expected release/launch window for a first biosimilar.

Source

[1] https://www.drugpatentwatch.com/